000186214 001__ 186214
000186214 005__ 20240229145735.0
000186214 0247_ $$2doi$$a10.1038/s41416-022-02071-3
000186214 0247_ $$2pmid$$apmid:36460776
000186214 0247_ $$2ISSN$$a0007-0920
000186214 0247_ $$2ISSN$$a1532-1827
000186214 0247_ $$2altmetric$$aaltmetric:139617422
000186214 037__ $$aDKFZ-2022-03011
000186214 041__ $$aEnglish
000186214 082__ $$a610
000186214 1001_ $$aSedlmeier, Anja M$$b0
000186214 245__ $$aBody shape phenotypes of multiple anthropometric traits and cancer risk: a multi-national cohort study.
000186214 260__ $$aEdinburgh$$bNature Publ. Group$$c2023
000186214 3367_ $$2DRIVER$$aarticle
000186214 3367_ $$2DataCite$$aOutput Types/Journal article
000186214 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677235116_26854
000186214 3367_ $$2BibTeX$$aARTICLE
000186214 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186214 3367_ $$00$$2EndNote$$aJournal Article
000186214 500__ $$a2023 Feb;128(4):594-605
000186214 520__ $$aClassical anthropometric traits may fail to fully represent the relationship of weight, adiposity, and height with cancer risk. We investigated the associations of body shape phenotypes with the risk of overall and site-specific cancers.We derived four distinct body shape phenotypes from principal component (PC) analysis on height, weight, body mass index (BMI), waist (WC) and hip circumferences (HC), and waist-to-hip ratio (WHR). The study included 340,152 men and women from 9 European countries, aged mostly 35-65 years at recruitment (1990-2000) in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).After a median follow-up of 15.3 years, 47,110 incident cancer cases were recorded. PC1 (overall adiposity) was positively associated with the risk of overall cancer, with a HR per 1 standard deviation (SD) increment equal to 1.07 (95% confidence interval 1.05 to 1.08). Positive associations were observed with 10 cancer types, with HRs (per 1 SD) ranging from 1.36 (1.30-1.42) for endometrial cancer to 1.08 (1.03-1.13) for rectal cancer. PC2 (tall stature with low WHR) was positively associated with the risk of overall cancer (1.03; 1.02-1.04) and five cancer types which were not associated with PC1. PC3 (tall stature with high WHR) was positively associated with the risk of overall cancer (1.04; 1.03-1.05) and 12 cancer types. PC4 (high BMI and weight with low WC and HC) was not associated with overall risk of cancer (1.00; 0.99-1.01).In this multi-national study, distinct body shape phenotypes were positively associated with the incidence of 17 different cancers and overall cancer.
000186214 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186214 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186214 7001_ $$aViallon, Vivian$$b1
000186214 7001_ $$00000-0001-9358-7338$$aFerrari, Pietro$$b2
000186214 7001_ $$aPeruchet-Noray, Laia$$b3
000186214 7001_ $$aFontvieille, Emma$$b4
000186214 7001_ $$aAmadou, Amina$$b5
000186214 7001_ $$00000-0001-6003-7794$$aSeyed Khoei, Nazlisadat$$b6
000186214 7001_ $$aWeber, Andrea$$b7
000186214 7001_ $$aBaurecht, Hansjörg$$b8
000186214 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b9
000186214 7001_ $$00000-0002-8452-8472$$aTsilidis, Kostas$$b10
000186214 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000186214 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b12$$udkfz
000186214 7001_ $$aInan-Eroglu, Elif$$b13
000186214 7001_ $$aSchulze, Matthias B$$b14
000186214 7001_ $$aOvervad, Kim$$b15
000186214 7001_ $$aBonet, Catalina$$b16
000186214 7001_ $$aUbago-Guisado, Esther$$b17
000186214 7001_ $$aChirlaque, María-Dolores$$b18
000186214 7001_ $$aArdanaz, Eva$$b19
000186214 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b20
000186214 7001_ $$00000-0001-5438-970X$$aPala, Valeria$$b21
000186214 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b22
000186214 7001_ $$aSacerdote, Carlotta$$b23
000186214 7001_ $$aPasanisi, Fabrizio$$b24
000186214 7001_ $$00000-0002-1741-2322$$aBorch, Kristin B$$b25
000186214 7001_ $$aRylander, Charlotta$$b26
000186214 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b27
000186214 7001_ $$aGunter, Marc J$$b28
000186214 7001_ $$aFervers, Béatrice$$b29
000186214 7001_ $$aLeitzmann, Michael F$$b30
000186214 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b31
000186214 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-022-02071-3$$n4$$p594-605$$tBritish journal of cancer$$v128$$x0007-0920$$y2023
000186214 909CO $$ooai:inrepo02.dkfz.de:186214$$pVDB
000186214 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000186214 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000186214 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186214 9141_ $$y2022
000186214 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-15$$wger
000186214 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-15
000186214 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-15
000186214 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-15
000186214 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2022$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000186214 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2022$$d2023-10-22
000186214 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000186214 980__ $$ajournal
000186214 980__ $$aVDB
000186214 980__ $$aI:(DE-He78)C020-20160331
000186214 980__ $$aUNRESTRICTED